JP2018510160A - ベクター製剤 - Google Patents

ベクター製剤 Download PDF

Info

Publication number
JP2018510160A
JP2018510160A JP2017549215A JP2017549215A JP2018510160A JP 2018510160 A JP2018510160 A JP 2018510160A JP 2017549215 A JP2017549215 A JP 2017549215A JP 2017549215 A JP2017549215 A JP 2017549215A JP 2018510160 A JP2018510160 A JP 2018510160A
Authority
JP
Japan
Prior art keywords
composition
virus
viral vector
vector
trehalose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017549215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510160A5 (enExample
Inventor
ロバート エイチ． カトナー，
ロバート エイチ． カトナー，
ウェスリー ゴーマン，
ウェスリー ゴーマン，
フランシス ジェイ． ジュニア ピアーシー，
フランシス ジェイ． ジュニア ピアーシー，
Original Assignee
ブルーバード バイオ， インコーポレイテッド
ブルーバード バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブルーバード バイオ， インコーポレイテッド, ブルーバード バイオ， インコーポレイテッド filed Critical ブルーバード バイオ， インコーポレイテッド
Publication of JP2018510160A publication Critical patent/JP2018510160A/ja
Publication of JP2018510160A5 publication Critical patent/JP2018510160A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2017549215A 2015-03-20 2016-03-18 ベクター製剤 Pending JP2018510160A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136309P 2015-03-20 2015-03-20
US62/136,309 2015-03-20
PCT/US2016/023271 WO2016154055A1 (en) 2015-03-20 2016-03-18 Vector formulations

Publications (2)

Publication Number Publication Date
JP2018510160A true JP2018510160A (ja) 2018-04-12
JP2018510160A5 JP2018510160A5 (enExample) 2019-04-25

Family

ID=56977784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549215A Pending JP2018510160A (ja) 2015-03-20 2016-03-18 ベクター製剤

Country Status (6)

Country Link
US (1) US20180094280A1 (enExample)
EP (1) EP3270960A4 (enExample)
JP (1) JP2018510160A (enExample)
CN (1) CN107614008A (enExample)
AU (1) AU2016235421A1 (enExample)
WO (1) WO2016154055A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020026968A1 (ja) * 2018-07-30 2020-02-06 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
JP2023504593A (ja) * 2019-11-12 2023-02-06 オックスフォード バイオメディカ（ユーケー）リミテッド 産生系

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
AU2016355323B2 (en) * 2015-11-19 2021-03-04 Novartis Ag Buffers for stabilization of lentiviral preparations
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
CN110300591A (zh) 2016-11-04 2019-10-01 百深公司 腺相关病毒制剂
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
KR20200131844A (ko) * 2018-03-16 2020-11-24 사이토이뮨 테라퓨틱스 인코퍼레이티드 이중특이적 항체 car 세포 면역요법
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
AU2019272848A1 (en) 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
MX2020013953A (es) 2018-07-11 2021-03-09 Takeda Pharmaceuticals Co Composiciones de virus adenoasociado (aav).
CN109134665B (zh) 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
CN111542343B (zh) * 2018-08-24 2023-08-18 上海先博生物科技有限公司 抗bcma的单域抗体及其应用
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
CN109157518B (zh) * 2018-09-26 2021-03-12 厚朴生物科技（苏州）有限公司 慢病毒载体冻干保存方法及制剂
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
AU2020211990A1 (en) * 2019-01-22 2021-08-12 2Seventy Bio, Inc. Methods and systems for manufacturing viral vectors
CN109825526A (zh) * 2019-02-15 2019-05-31 北京门罗生物科技有限公司 一种用于通用型car-t制备的重组腺相关病毒载体及其构建方法和应用
CN109777782A (zh) * 2019-02-15 2019-05-21 北京门罗生物科技有限公司 一种通用型car-t细胞及其制备方法和用途
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
CA3141712A1 (en) 2019-05-24 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
EP4013436A1 (en) * 2019-08-14 2022-06-22 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
CN110760007B (zh) * 2019-11-21 2022-08-26 博生吉医药科技(苏州)有限公司 Cd7-car-t细胞及其制备和应用
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
AU2020393917A1 (en) 2019-11-29 2022-06-23 Paros Bio, Inc. Gene therapy for neurodegenerative disorders
CN116096904A (zh) * 2019-12-31 2023-05-09 天鹅生物疗法有限公司 改进的aav-abcd1构建体和用于治疗或预防肾上腺脑白质营养不良(ald)和/或肾上腺脊髓神经病(amn)的用途
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
JP2023516008A (ja) 2020-02-27 2023-04-17 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
CN113549653B (zh) * 2020-04-23 2024-03-22 上海赛比曼生物科技有限公司 用于慢病毒载体长期存贮的组合试剂
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
EP4388000A1 (en) 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
JP2026519263A (ja) 2022-10-26 2026-06-15 ノバルティス アーゲー レンチウイルス製剤

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02503266A (ja) * 1988-01-21 1990-10-11 クアドラント　バイオリソースイズ、リミテッド ウイルスの保存
JPH09504429A (ja) * 1993-10-12 1997-05-06 チロン ビアジーン，インコーポレイティド 組換えウイルスの保存方法
JP2001510053A (ja) * 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
US20020031527A1 (en) * 1998-11-16 2002-03-14 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
JP2002531119A (ja) * 1998-12-10 2002-09-24 ジェンベク、インコーポレイティッド ウイルスを保存するための方法および組成物
JP2010523127A (ja) * 2007-04-06 2010-07-15 インビラジェン， インコーポレイテッド 弱毒生ウイルスのための方法および組成物
JP2013515748A (ja) * 2009-12-28 2013-05-09 リゴサイト ファーマシューティカルズ インコーポレイテッド インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
WO2014140645A1 (en) * 2013-03-15 2014-09-18 Arecor Limited Stable aqueous formulations of adenovirus vectors
WO2014201319A1 (en) * 2013-06-14 2014-12-18 The University Of Houston System Targeting tumor neovasculature with modified chimeric antigen receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133316B1 (en) * 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US8772021B2 (en) * 2005-03-04 2014-07-08 Celltrion, Inc. Expression vector for animal cell comprising at least one copy of MAR DNA sequences at the 3′ terminal of transcription termination region of a gene and method for the expression of foreign gene using the vector
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2010100278A2 (en) * 2009-03-06 2010-09-10 Europäisches Laboratorium für Molekularbiologie (EMBL) Nucleic acids for cloning and expressing multiprotein complexes
CN102438658A (zh) * 2009-03-13 2012-05-02 莱蒂恩公司 非整合型逆转录病毒载体疫苗
DK2717922T3 (en) * 2011-06-10 2019-01-07 Bluebird Bio Inc GENERATIVE VECTORS FOR ADDRENOLEUCODYSTROPHY AND ADDRENOMYELONE EUROPE
AU2013246443B2 (en) * 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02503266A (ja) * 1988-01-21 1990-10-11 クアドラント　バイオリソースイズ、リミテッド ウイルスの保存
JPH09504429A (ja) * 1993-10-12 1997-05-06 チロン ビアジーン，インコーポレイティド 組換えウイルスの保存方法
JP2001510053A (ja) * 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
US20020031527A1 (en) * 1998-11-16 2002-03-14 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
JP2002531119A (ja) * 1998-12-10 2002-09-24 ジェンベク、インコーポレイティッド ウイルスを保存するための方法および組成物
JP2010523127A (ja) * 2007-04-06 2010-07-15 インビラジェン， インコーポレイテッド 弱毒生ウイルスのための方法および組成物
JP2013515748A (ja) * 2009-12-28 2013-05-09 リゴサイト ファーマシューティカルズ インコーポレイテッド インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
WO2014140645A1 (en) * 2013-03-15 2014-09-18 Arecor Limited Stable aqueous formulations of adenovirus vectors
WO2014201319A1 (en) * 2013-06-14 2014-12-18 The University Of Houston System Targeting tumor neovasculature with modified chimeric antigen receptors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020026968A1 (ja) * 2018-07-30 2020-02-06 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
JPWO2020026968A1 (ja) * 2018-07-30 2021-08-12 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
JP2024084843A (ja) * 2018-07-30 2024-06-25 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
US12188040B2 (en) 2018-07-30 2025-01-07 Gene Therapy Research Institution Co., Ltd. Method for enhancing gene expression using AAV vector
JP7847610B2 (ja) 2018-07-30 2026-04-17 株式会社ONODERA GT Pharma Ａａｖベクターによる遺伝子発現を増強する方法
JP2023504593A (ja) * 2019-11-12 2023-02-06 オックスフォード バイオメディカ（ユーケー）リミテッド 産生系

Also Published As

Publication number Publication date
EP3270960A4 (en) 2018-08-08
WO2016154055A1 (en) 2016-09-29
EP3270960A1 (en) 2018-01-24
CN107614008A (zh) 2018-01-19
AU2016235421A1 (en) 2017-10-12
US20180094280A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
US20180094280A1 (en) Vector formulations
JP7536808B2 (ja) 養子細胞療法薬を製造するための改善された方法
JP6606210B2 (ja) Ｍｎｄプロモーターのキメラ抗原受容体
CN107207598B (zh) Bcma嵌合抗原受体
JP2026067851A (ja) 標的化脂質粒子及び組成物ならびにその使用
KR20210045985A (ko) 항-bcma 키메라 항원 수용체의 용도
US20250059239A1 (en) Modified paramyxoviridae fusion glycoproteins
US20240408192A1 (en) Modified paramyxoviridae attachment glycoproteins
CN119546328A (zh) 多部分受体和信号传导复合物
US20190365814A1 (en) Vcn enhancer compositions and methods of using the same
CN116348496A (zh) Bcma嵌合抗原受体
US20240261404A1 (en) Modified ccr polypeptides and uses thereof
JP2025504398A (ja) Ｍｕｃ１６キメラ抗原受容体
KR20230113755A (ko) 선행 항암 알킬화제 요법을 받은 환자에서의 car t 세포 요법
AU2024274792A1 (en) Tandem fusogens and related lipid particles
CN116888474A (zh) 嵌合抗原受体(car)t细胞疗法与炎症相关可溶性因子抑制剂的组合用途
KR20230171994A (ko) 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
WO2025184529A1 (en) Viral particles with fusogen display and related compositions and methods
CN116802743A (zh) 曾经历先前抗癌烷化剂疗法的患者中的car t细胞疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201217